$AIMAug 10, 2026, 12:36 PMAI processed

AIM completes enrollment and dosing in Phase 2 pancreatic cancer trial; DURIPANC data expected Q1/Q3 2027

AI Summary

AIM ImmunoTech (AIM) completed enrollment and dosing in the Phase 2 DURIPANC study of Ampligen plus durvalumab in metastatic pancreatic cancer and says it expects clinical benefit data in Q1 2027 and overall survival data in Q3 2027. The company engaged Thermo Fisher PPD to support Phase 3 design, reported $9.9M cash at June 30, 2026 and regained NYSE American compliance, but no efficacy readouts have yet been reported.

Positives

Completed enrollment and Ampligen dosing in Phase 2 DURIPANC trial (Ampligen + durvalumab) in metastatic pancreatic cancer
Company expects clinical benefit data in Q1 2027 and overall survival (OS) data in Q3 2027
Reported $9.9M cash and cash equivalents as of June 30, 2026

Negatives

No efficacy or survival readouts yet; key data are pending
Net loss of $(3.8M) for Q2 2026
General and administrative expense rose to $2.9M in Q2 2026 (up from $1.5M year-over-year)

Company Info

Company:: AIM ImmunoTech Inc
Exchange:: Nyse Mkt Llc
Industry:: Biotechnology
Country:: US
Website:: https://aimimmuno.com
Market cap:: 7.18M
Shares outstanding:: 27.72M

Now available

TradersLink Beta App

Free beta access for all TradersLink Discord members(free and premium members)

Daily Trade Tracker

Enter the executions you took each day and TradersLink builds the trades for you. Review them by ticker with trade replay charts, then add trade notes, tags, and rules. Finish the day with what went well, what to work on, and your main focus for next time.

Trade Analyzer

Analyze every trade—not just your totals. Review detailed entry, exit, and complete-trade analysis, then use long-term results to study your execution habits over time. See missed profit opportunities, exits that may have happened too early, and trades that were green before they finished red. Candle-pattern data helps you study the conditions around your entries and exits.

Smart Rules

Use preset trading rules that TradersLink can track from your recorded trades. Review when a rule may have been broken, see your results over time, and create custom rules for your own process.

Press Release Alerts

Get press-release alerts inside your dashboard, including alerts when a stock is halted, so important news is visible while you track your trades.

Trade Explorer

Open a completed trade and go deeper. Review its executions, result, notes, tags, rules, and analysis in one place.

Analytics

Understand your trading history from more than one angle. Explore results by ticker, time of day, holding time, setups, and other patterns supported by your recorded trades.